MedTrace Logo

CRP on Radiobiological and Clinical Studies on Viral-Induced Cancer's Response to Radiotherapy

NCT00122772 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 601

Last updated 2011-10-14

No results posted yet for this study

Summary

The purpose of this trial is to study clinical effects of two/four high dose rate (HDR) brachytherapy applications and teletherapy with or without weekly cisplatin in cervix cancer.

Conditions

  • Cervix Cancer

Interventions

RADIATION

Radiotherapy

External Beam Radiation 46Gy in 23 daily fractions High Dose Brachytherapy 2 fractions of 9Gy

RADIATION

Radiotherapy

External Beam Radiotherapy 46Gy in 23 daily fractions High Dose Brachytherapy 4 fractions of 7Gy

RADIATION

Radiotherapy/Cisplatin

External Beam Radiation 46Gy in 23 daily fractions High Dose Brachytherapy 2 fractions of 9Gy Cisplatin 40 mg/sqm weekly

RADIATION

Radiotherapy/Cisplatin

External Beam Radiotherapy 46Gy in 23 daily fractions High Dose Brachytherapy 4 fractions of 7Gy Cisplatin 40mg/sqm weekly

Sponsors & Collaborators

  • International Atomic Energy Agency

    lead OTHER_GOV

Principal Investigators

  • Eduardo H. Zubizarreta, M.D. · International Atomic Energy Agency (IAEA)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-11-30
Primary Completion
2010-06-30
Completion
2010-06-30

Countries

  • Austria
  • Brazil
  • Canada
  • India
  • Morocco
  • North Macedonia
  • Pakistan
  • Peru
  • South Africa
  • South Korea
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00122772 on ClinicalTrials.gov